Although the United States exceeded its vaccination goals since February 2021, the outcome hasn’t been flawless. A factory mix-up ruined up to 15 million doses of the single-shot Johnson & Johnson vaccine when a subcontractor mixed the ingredients from it with the AstraZeneca product.
Since the AstraZeneca vaccine is not available for distribution in the United States, the product was not usable.
The plant is run by Emergent BioSolutions, which partners with both single-shot producers. Regulators attributed the issue to human error, causing Johnson & Johnson to step up quality control procedures at the facility.
One Shot Speeds Up the Immunity Process in the United States
Although the two-shot vaccines for COVID-19 came out first, the Johnson & Johnson product receives a lot of credit for speeding along the immunity-building process in the United States. Once someone gets this shot, they’re considered immune after two weeks.
The setback was a major embarrassment for both companies involved in vaccine production. It would soon be followed by revelations that a rare side effect of the Johnson & Johnson vaccine involves blood clots that can appear three weeks after it gets administered.
To make up for the gap in vaccination opportunities, Pfizer started shipping its doses early. Moderna requested approval to send vials with 15 shots instead of ten to bolster the stock even further.
None of the tainted doses ever left the production facility. The mishap was reported to regulators immediately, and steps are in place to prevent future lapses.
The error has not affected any of the already delivered Johnson & Johnson doses. Additional deliveries from the Baltimore facility continue to remain in question.